GB/T 16886.16-2021 PDF in English
GB/T 16886.16-2021 (GB/T16886.16-2021, GBT 16886.16-2021, GBT16886.16-2021)
| Standard ID | Contents [version] | USD | STEP2 | [PDF] delivered in | Name of Chinese Standard | Status |
| GB/T 16886.16-2021 | English | 260 |
Add to Cart
|
0-9 seconds. Auto-delivery.
|
Biological evaluation of medical devices -- Part 16: Toxicokinetic study design for degradation products and leachables
| Valid |
| GB/T 16886.16-2013 | English | 145 |
Add to Cart
|
0-9 seconds. Auto-delivery.
|
Biological evaluation of medical devices -- Part 16: Toxicokinetic study design for degradation products and leachables
| Obsolete |
| GB/T 16886.16-2003 | English | 439 |
Add to Cart
|
3 days
|
Biological evaluation of medical devices -- Part 16: Toxicokinetic study design for degradation products and leachable
| Obsolete |
Standards related to (historical): GB/T 16886.16-2021
PDF Preview
GB/T 16886.16-2021: PDF in English (GBT 16886.16-2021) GB/T 16886.16-2021
NATIONAL STANDARD OF THE
PEOPLE’S REPUBLIC OF CHINA
ICS 11.100.20
CCS C 30
GB/T 16886.16-2021 / ISO 10993-16:2017
Replacing GB/T 16886.16-2013
Biological Evaluation of Medical Devices – Part 16:
Toxicokinetic Study Design for Degradation Products and
Leachables
降解产物与可沥滤物毒代动力学研究设计
(ISO 10993-16:2017, IDT)
ISSUED ON: NOVEMBER 26, 2021
IMPLEMENTED ON: DECEMBER 01, 2022
Issued by: State Administration for Market Regulation;
Standardization Administration of the People’s Republic of China.
Table of Contents
Foreword ... 3
Introduction ... 6
1 Scope ... 9
2 Normative References ... 9
3 Terms and Definitions ... 9
4 Principles for Design of Toxicokinetic Studies ... 11
5 Guidance on Test Methods ... 12
5.1 General considerations ... 12
5.2 Guidance on specific types of test ... 14
5.2.1 General ... 14
5.2.2 Absorption ... 14
5.2.3 Distribution ... 14
5.2.4 Metabolism and excretion ... 15
Annex A (Normative) Circumstances in which Toxicokinetic Studies shall be
Considered ... 17
Bibliography ... 19
Foreword
This Document was drafted as per the rules specified in GB/T 1.1-2020 Directives for
Standardization – Part 1: Rules for the Structure and Drafting of Standardizing Documents.
This Document is the Part 16 of GB/T 16886 Biological Evaluation of Medical Devices. GB/T
16886 has issued the following parts:
--- Part 1: Evaluation and Testing within a Risk Management Process;
--- Part 2: Animal Welfare Requirements;
--- Part 3: Tests for Genotoxicity, Carcinogenicity and Reproductive Toxicity;
--- Part 4: Selection for Tests for Interactions with Blood;
--- Part 5: Tests for Cytotoxicity: in Vitro Methods;
--- Part 6: Tests for Local Effects after Implantation;
--- Part 7: Ethylene Oxide Sterilization Residuals;
--- Part 9: Framework for Identification and Quantification of Potential Degradation
Products;
--- Part 10: Tests for Irritation and Skin Sensitization;
--- Part 11: Tests for Systemic Toxicity;
--- Part 12: Sample Preparation and Reference Materials;
--- Part 13: Identification and Quantification of Degradation Products from Polymeric
Medical Devices;
--- Part 14: Identification and Quantification of Degradation Products from Ceramics;
--- Part 15: Identification and Quantification of Degradation Products from Metals and
Alloys;
--- Part 16: Toxicokinetic Study Design for Degradation products and Leachables;
--- Part 17: Establishment of Allowable Limits for Leachable Substances;
--- Part 18: Chemical Characterization of Materials;
--- Part 19: Physico-Chemical, Morphological and Topographical Characterization of
Materials;
--- Part 20: Principles and Methods for Immunotoxicology Testing of Medical Devices.
This Document replaced GB/T 16886.16-2013 Biological Evaluation of Medical Devices - Part
16: Toxicokinetic Study Design for Degradation Products and Leachables. Compared with
GB/T 16886.16-2013, the major technical changes of this Document are as follows besides the
editorial modifications:
--- Modify the definition of term “Absorption” (see 3.1 of this Edition; 3.1 of 2013 Edition);
--- Modify "Principles for design of toxicokinetic studies" (see Clause 4 of this Edition;
Clause 4 of 2013 Edition);
--- Modify the "Guidance on test methods" (see Clause 5 of this Edition; Clause 5 of 2013
Edition);
--- Add information on toxicokinetic studies of nanomaterials (see A.4 of this Edition);
--- Modify the circumstances that shall be considered in toxicokinetic studies (see A.4 of
this Edition; A.4 of 2013 Edition).
This Document used translation method to equivalently adopt ISO 10993-16:2017 Biological
Evaluation of Medical Devices – Part 16: Toxicokinetic Study Design for Degradation Products
and Leachables.
The Chinese document that has a consistent correspondence with the international documents
normatively cited in this document is as follows:
--- GB/T 16886.1-2011 Biological Evaluation of Medical Devices - Part 1: Evaluation and
Testing within a Risk Management Process (ISO 10993-1:2009, IDT).
Please note some contents of this Document may involve patents. The issuing agency of this
Document shall not assume the responsibility to identify these patents.
This Document was proposed by National Medical Products Administration.
This Document shall be under the jurisdiction of National Technical Committee on Biological
Evaluation on Medical Device of Standardization Administration of China (SAC/TC 248).
Drafting organizations of this Document: Shandong Quality Inspection Center for Medical
Device; and Shandong University.
Chief drafting staffs of this Document: Fan Chunguang, Liu Chenghu, Hou Li, Zhang Na, Liu
Xiangdong, and Dong Xiuli.
The historical editions replaced by this Document are as follows:
--- GB/T 16886.16-2003 was first-time published in 2003; first-time revised in 2013;
Biological Evaluation of Medical Devices – Part 16:
Toxicokinetic Study Design for Degradation Products and
Leachables
1 Scope
This Document provides principles on designing and performing toxicokinetic studies relevant
to medical devices. Annex A describes the considerations for inclusion of toxicokinetic studies
in the biological evaluation of medical devices.
This Document applies to toxicokinetic studies of medical device degradation products and
leachables.
2 Normative References
The provisions in following documents become the essential provisions of this Document
through reference in this Document. For the dated documents, only the versions with the dates
indicated are applicable to this Document; for the undated documents, only the latest version
(including all the amendments) is applicable to this Document.
ISO 10993-1 Biological Evaluation of Medical Devices – Part 1: Evaluation and Testing
within a Risk Management Process
3 Terms and Definitions
For the purposes of this Document, the terms and definitions given in ISO 10993-1 and the
following apply.
ISO and IEC maintain terminological databases for use in standardization at the following
addresses:
--- IEC Electropedia: available at http://www.electropedia.org/;
--- ISO Online browsing platform: available at http://www.iso.org/obp.
3.1 Absorption
Process of uptake of substance into or across tissue, blood and/or lymph system.
......
Source: Above contents are excerpted from the PDF -- translated/reviewed by: www.chinesestandard.net / Wayne Zheng et al.
|